By Fineline Cube 
Vivatides Therapeutics announced the completion of an oversubscribed USD 54 million Series A financing round, positioning the company to accelerate development of its proprietary extrahepatic oligonucleotide delivery technology platform.
Financing Details
| Item | Detail |
|---|---|
| Amount Raised | USD 54 million |
| Round | Series A (oversubscribed) |
| Co-Lead Investors | Qiming Venture Partners, Prominent Industrial Fund |
| Participating Investors | Highlight Capital, TF Capital, Apricot Capital (returning) |
| Announcement Date | 12 Apr 2026 |
| Use of Proceeds | Platform optimization, clinical advancement, team expansion, global R&D network |
Company Profile & Technology Focus
- Founded: 2025
- Headquarters: Suzhou, China
- Core Focus: Innovation and translation of extrahepatic oligonucleotide delivery technologies
- Therapeutic Scope: Addressing unmet medical needs in tissues beyond the liver
- Team Expertise: International core team comprising seasoned experts from global oligonucleotide leaders (Arrowhead, Ionis, Alnylam, Dicerna)
- Track Record: Team members have previously led multiple extrahepatic pipeline developments, with several projects already advanced into clinical development
Strategic Significance
- Market Opportunity: Extrahepatic delivery represents one of the most significant barriers in oligonucleotide therapeutics, with successful solutions potentially unlocking treatments for numerous diseases currently inaccessible to RNA-targeted therapies
- Competitive Advantage: Deep collective expertise from industry veterans who have built and advanced multiple extrahepatic platforms at leading companies
- Development Strategy: Iterative optimization of proprietary delivery platform combined with parallel advancement of multiple pipeline assets
- Global Expansion: Establishment of international R&D network to accelerate innovation and clinical translation
Forward‑Looking Statements
This brief contains forward-looking statements regarding Vivatides Therapeutics’ development plans, platform advancement, and strategic objectives. Actual results may differ due to risks including technical challenges in extrahepatic delivery, regulatory requirements, and competitive dynamics in the oligonucleotide therapeutics field.-Fineline Info & Tech